Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Harvard Business School
AstraZeneca
Merck
Medtronic

Last Updated: August 13, 2022

Details for Patent: 5,935,946


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 5,935,946
Title: Nucleotide analog composition and synthesis method
Abstract:The invention provides a composition comprising bis(POC)PMPA and fumaric acid (1:1). The composition is useful as an intermediate for the preparation of antiviral compounds, or is useful for administration to patients for antiviral therapy or prophylaxis. The composition is particularly useful when administered orally. The invention also provides methods to make PMPA and intermediates in PMPA synthesis. Embodiments include lithium t-butoxide, 9-(2-hydroxypropyl) adenine and diethyl p-toluenesulfonylmethoxyphosphonate in an organic solvent such as DMF. The reaction results in diethyl PMPA preparations containing an improved by-product profile compared to diethyl PMPA made by prior methods.
Inventor(s): Munger, Jr.; John D. (Alviso, CA), Rohloff; John C. (Mountain View, CA), Schultze; Lisa M. (San Carlos, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:08/900,752
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,935,946
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Use; Dosage form; Process;

Drugs Protected by US Patent 5,935,946

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 5,935,946

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 228526 See Plans and Pricing
Austria 288914 See Plans and Pricing
Austria 305009 See Plans and Pricing
Australia 756793 See Plans and Pricing
Australia 8582798 See Plans and Pricing
Brazil 9811045 See Plans and Pricing
Canada 2298059 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Colorcon
AstraZeneca
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.